By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the company to repurchase up to the lesser of $22.75 million worth of its common stock or 650,000 shares, the firm said in a document filed today with the US Securities and Exchange Commission.

In the filing, the Austin, Texas-based firm said that it may repurchase its stock in the open market from time to time or in privately negotiated transactions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.